Safe, affordable, and scalable off-the shelf natural killer (NK) cell therapeutics

CAR-T cells are an important and effective tool in the treatment of selected patients with different cancers, but they have limitations, including adverse effects from cytokine release syndrome and neurotoxicity, limited success with solid tumors, high manufacturing cost, and the challenge of generating off-the shelf products.

The process of collecting, genetically modifying, and expanding patient-derived T cells takes 2-3 weeks and costs an average of$250,000 to manufacture therapeutic doses for each patient.

CAR-NK cells are effective in treating cancers without the side effects associated with CAR-T cell therapy and offer strategies to overcome immune suppression from the solid tumour microenvironment.

Tech Overview
Unique portfolio of intellectual property assets and technologies combine expertise and access to proprietary assets in gene editing technologies, induced pluripotent stem cell (iPSC) line generation capabilities, and state-of-the-art cGMP cell manufacturing facilities.

Proprietary chimeric antigen receptor (CAR) platform is optimized for NK cells to overcome the immunosuppressive tumor microenvironment and maintain functional persistence.

The platform leverages a limitless source of donor-independent iPSCs that can be readily engineered and differentiated to NK cells. Engineered iPSC-derived NK cells can be administered as off-the-shelf, highly effective, accessible, and affordable medicines without the need for patient matching

ecommSafe, affordable, and scalable off-the shelf natural killer (NK) cell therapeutics